Upper Stomach – CancerObesityConnection.org

Upper Stomach Cancer - Obesity, Recent Papers, and Clinical Trials

To see all 14 Papers, go directly to PubMed.

RECENT PAPERS from PubMed – November 12. 2023 -Stomach Cancer (in title) AND Obesity

Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study July 2, 2025
BACKGROUND: Both obesity and diabetes are associated with increased risk for specific types of cancer, generally termed obesity-related cancer (ORC). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and bariatric metabolic surgery (BMS) are well established treatments for diabetes and obesity, but their comparative effectiveness for the prevention of ORC is unknown. Here, we compare the incidence […]
Yael Wolff Sagy
Clinical benefits including the postoperative inflammatory status of robot-assisted distal gastrectomy for gastric cancer compared with laparoscopic distal gastrectomy in patients with obesity April 10, 2025
This study aimed to clarify the clinical benefits of robot-assisted distal gastrectomy (RDG) versus laparoscopic distal gastrectomy (LDG) in patients with obesity.The analysis included 89 and 87 patients in LDG and RDG groups, respectively. The associations between body mass index (BMI) and surgical outcomes including postoperative inflammation were compared between LDG and RDG.Incidences of postoperative […]
Kazuaki Matsui
Hand Grip Strength and Body Composition According to the Sarcopenic Obesity Guidelines: Impact on Postoperative Complications in Patients With Gastric Cancer April 8, 2025
CONCLUSIONS: In obese patients with gastric cancer, the preoperative prevalence of low HGS-obesity or low SMM-obesity differed significantly. One of the low SMM-obesity model was associated with postoperative complication after gastrectomy.
Yoko Saino
Impact of sarcopenic obesity on postoperative outcomes in patients with oesophago-gastric cancer: A systematic review and meta-analysis December 26, 2024
CONCLUSIONS: Sarcopenic obesity worsens OS and increases the risk of postoperative complications in patients with oesophago-gastric cancer undergoing radical resection.
Ryota Matsui
Prevalence of sarcopenic obesity in patients with gastric cancer and effects on adverse outcomes: A meta-analysis and systematic review October 22, 2024
CONCLUSIONS: The prevalence of sarcopenic obesity is high in patients with gastric cancer and is strongly associated with poor postoperative outcomes. Healthcare providers should evaluate patients with gastric cancer for sarcopenic obesity early to prevent or reduce the incidence of adverse outcomes.
Bingyan Zhao
Association between different patterns of obesity and the short-term outcomes of gastric cancer surgery October 17, 2024
Previous studies have shown that general and central obesity are each linked to adverse outcomes in gastrointestinal cancers. However, their combined effect on gastrointestinal cancers surgery outcomes were less understood. This study aims to integrate both general and central obesity to examine the outcomes of gastric cancer surgery in different obesity patterns. We retrospectively analyzed […]
Guoqing Shi
A case report of Roux-en-Y gastric bypass combined with radical gastrectomy for severe obesity complicated with gastric cancer September 23, 2024
No abstract
J D Li
Obesity and its relationship with cancer September 16, 2024
The aim of this study is to investigate how excess weight can influence cancer risk and the possible mechanisms involved. For this purpose, a bibliographic review was made of the studies published between 2000 and 2024 that analyze this relationship, as well as specific types of cancer associated with obesity. A significant association was found […]
Ovidio Hernando-Requejo
Impact of visceral fat obesity (obesity disease) on short- and long-term outcomes of laparoscopic gastrectomy in gastric cancer August 27, 2024
CONCLUSION: Visceral fat accumulation strongly predicted postoperative morbidity. Despite increased perioperative risk, OD did not negatively impact successful lymphadenectomy or survival following LG.
Kei Yamamoto
Methylsulfinyl Hexyl Isothiocyanate (6-MSITC) from Wasabi Is a Promising Candidate for the Treatment of Cancer, Alzheimer's Disease, and Obesity August 10, 2024
Methylsulfinyl hexyl isothiocyanate (6-MSITC) isolated from Eutrema japonicum is a promising candidate for the treatment of breast cancer, colorectal and stomach cancer, metabolic syndrome, heart diseases, diabetes, and obesity due to its anti-inflammatory and antioxidant properties. Also, its neuroprotective properties, improving cognitive function and protecting dopaminergic neurons, make it an excellent candidate for treating neurodegenerative […]
Joanna Bartkowiak-Wieczorek
Sarcopenic obesity predicts short- and long-term outcomes after neoadjuvant chemotherapy and surgery for gastric cancer June 28, 2024
CONCLUSIONS: Pre-NAC SO was an independent prognostic factor in patients with LAGC undergoing NAC; post-NAC SO independently predicted postoperative morbidity.
Chunning Duan
Systematic review and meta-analysis of short-term outcomes: robot-assisted versus laparoscopic surgery for gastric cancer patients with visceral obesity June 4, 2024
The objective of this meta-analysis was to assess the comparative efficacy of robot-assisted and laparoscopic surgery in treating gastric cancer among patients characterized by a high visceral fat area (VFA). In April 2024, we conducted a comprehensive literature review using major international databases, such as PubMed, Embase, and Google Scholar. We restricted our selection to […]
Lin-Wen Yang
Fat mass and obesity-associated protein (FTO) mediated m(6)A modification of circFAM192A promoted gastric cancer proliferation by suppressing SLC7A5 decay March 31, 2024
Gastric cancer (GC) is a common malignant tumor worldwide, especially in East Asia, with high incidence and mortality rate. Epigenetic modifications have been reported to participate in the progression of gastric cancer, among which m⁶A is the most abundant and important chemical modification in RNAs. Fat mass and obesity-associated protein (FTO) is the first identified […]
Xi Wu
Muscle attenuation, not skeletal muscle index, is an independent prognostic factor for survival in gastric cancer patients with overweight and obesity March 9, 2024
CONCLUSION: MA had a higher prognostic value than SMI in overweight and obese patients with gastric cancer after radical gastrectomy.
Cheng-Le Zhuang
The influence of Helicobacter pylori, proton pump inhibitor, and obesity on the gastric microbiome in relation to gastric cancer development December 11, 2023
Helicobacter pylori infection is still the main risk factor for the development of gastric cancer (GC). We explore the scientific evidence for the role of the gastric microbiome beyond Helicobacter pylori (H. pylori) in gastric carcinogenesis. The composition of the gastric microbiome in healthy individuals, in presence and absence of H. pylori infection, in proton […]
Chengliang Zhou
The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer September 28, 2023
CONCLUSION: Sarcopenia is more prevalent in the elderly population and is linked to increased mortality in gastric cancer patients. Paradoxically, higher body mass index (BMI) was associated with improved survival. Computed tomography offers a practical and reliable method for measuring muscle mass and distinguishing these distinctions.
Muzaffer Ece Hakan Şahin
Pre-diagnosis lipid levels and mortality after obesity-related cancer diagnosis in the Women's Health Initiative cardiovascular disease biomarker cohort June 29, 2023
CONCLUSIONS: The relationship between pre-diagnosis fasting lipid levels and mortality after cancer diagnosis is complex. These results suggest that improved lipid control through lifestyle and anti-lipid medications could have a meaningful impact on outcomes after cancer.
Gayane Hovsepyan
Gastric Cancer Risk in Association with Underweight, Overweight, and Obesity: A Systematic Review and Meta-Analysis June 22, 2023
This study aimed to investigate the risk of gastric cancer (GC) in abnormal body mass index (BMI) groups. A systematic search was carried out on Embase, PubMed/Medline, and Scopus from January 2000 to January 2023. The pooled risk ratio (RR) with a 95% confidence interval (CI) was assessed using a random-effect model. Thirteen studies with […]
Narges Azizi
Obesity paradox as a new insight from postoperative complications in gastric cancer June 21, 2023
The obesity paradox is reported to exist in various diseases. However, obesity is a pivotal issue in gastric cancer (GC) patients because of the surgical difficulty related to postoperative abdominal infectious complications (PAIC). This study clarified the existence of the obesity paradox in GC. Between 1997 and 2015, 1536 consecutive patients underwent curative gastrectomy. Of […]
Hajime Kamiya
Propensity score matching comparisons of postoperative complications and morbidity between digestive tract reconstruction methods after gastrectomy in gastric cancer patients with visceral obesity March 2, 2023
CONCLUSIONS: B-I reconstruction was associated with decreased overall postoperative complications, rather than OS, in GC patients with VO who underwent gastrectomy.
Chenchen Mao

Clinical Trials involving Stomach Cancer and Obesity

NCT Number	Study Title	Study URL	Acronym	Study Status	Interventions	Sponsor	Collaborators	Enrollment	Study Type	Locations
NCT05874726	Biological Sample Repository for Gastrointestinal Disorders	https://clinicaltrials.gov/study/NCT05874726		RECRUITING	DIAGNOSTIC_TEST: Blood Collection\|DIAGNOSTIC_TEST: Urine Collection\|DIAGNOSTIC_TEST: Tissue Sample Collection	Pichamol Jirapinyo, MD, MPH	Tufts University\|Boston Children's Hospital\|Mayo Clinic	500	OBSERVATIONAL	Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States
NCT00535990	Minimally Invasive Surgery (MIS) Database for the Purpose of Research	https://clinicaltrials.gov/study/NCT00535990		COMPLETED		University of California, San Diego		250	OBSERVATIONAL	University of California, San Diego, San Diego, California, 92103, United States
NCT01793168	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford	https://clinicaltrials.gov/study/NCT01793168	CoRDS	RECRUITING		Sanford Health	National Ataxia Foundation\|International WAGR Syndrome Association\|4p- Support Group\|ML4 Foundation\|Cornelia de Lange Syndrome Foundation\|Stickler Involved People\|Kawasaki Disease Foundation\|Klippel-Feil Syndrome Alliance\|Klippel-Feil Syndrome Freedom\|Hyperacusis Research Limited\|Hypersomnia Foundation\|Kabuki Syndrome Network\|Kleine-Levin Syndrome Foundation\|Leiomyosarcoma Direct Research Foundation\|Marinesco-Sjogren Syndrome Support Group - NORD\|Mucolipidosis Type IV (ML4) Foundation\|People with Narcolepsy 4 People with Narcolepsy (PWN4PWN)\|Soft Bones Incorporated\|American Multiple Endocrine Neoplasia Support\|Atypical Hemolytic Uremic Syndrome Foundation\|All Things Kabuki\|Wiedemann-Steiner Syndrome Foundation\|Breast Implant Victim Advocates\|PROS Foundation\|American Behcet's Disease Association\|Alstrom United Kingdom\|Athymia\|Curing Retinal Blindness Foundation\|HSAN1E Society\|1p36 Deletion Support and Awareness\|The Alagille Syndrome Alliance\|Autoinflammatory Alliance\|Beyond Batten Disease Foundation\|Bohring-Opitz Syndrome Foundation, INC\|Cockayne Syndrome Network (Share and Care)\|CRMO Foundation\|Cure VCP Disease,INC\|FOD Support\|Cystinosis Research Foundation\|Global DARE Foundation\|Hypnic Jerk-Sleep Myoclonus Support Group\|Jansen's Foundation\|KCNMA1 Channelopathy International Advocacy Foundation\|Kawasaki Disease Foundation Australia\|Life with LEMS Foundation\|Lowe Syndrome Association\|The Malan Syndrome Foundation\|Maple Syrup Urine Disease Family Support Group\|International Association for Muscle Glycogen Storage Disease (IamGSD)\|Myhre Syndrome Foundation\|DNM1 Families\|Nicolaides Baraitser Syndrome (NCBRS) Worldwide Foundation\|The PBCers Organization\|Pitt Hopkins Research Foundation\|Progressive Familial Intrahepatic Cholestasis Advocacy and Resource Network, Inc\|Recurrent Meningitis Association\|Recurrent Respiratory Papillomatosis Foundation\|Remember the Girls\|Smith-Kingsmore Syndrome Foundation\|SPG Research Foundation\|Team Telomere\|Transient Global Amnesia Project\|The Charlotte & Gwenyth Gray Foundation\|The Cute Syndrome Foundation\|The Maddi Foundation\|White Sutton Syndrome Foundation\|Zmynd11 Gene Disorder\|Cauda Equina Foundation, Inc\|Tango2 Research Foundation\|Noah's Hope - Hope4Bridget Foundation\|Project Sebastian\|SMC1A Epilepsy Foundation\|International Foundation for Gastrointestinal Disorders\|Endosalpingiosis Foundation, Inc\|International Sacral Agenesis/Caudal Regression Association (ISACRA)\|Scheuermann's Disease Fund\|Batten Disease Support and Research Association\|Kennedy's Disease Association\|Cure Mito Foundation\|Warburg Micro Research Foundation\|Cure Mucolipidosis\|Riaan Research Initiative\|CureARS A NJ Nonprofit Corporation\|CACNA1H Alliance\|IMBS Alliance\|SHINE-Syndrome Foundaion\|Non- Ketotic Hyperglycinemia (NKH) Crusaders\|Hypertrophic Olivary Degeneration Association (HODA)\|National Organization for Disorders of the Corpus Callosum (NODCC)	20000	OBSERVATIONAL	Sanford Health, Sioux Falls, South Dakota, 57104, United States\|Online Patient Enrollment System, Sydney, Australia
NCT04068896	Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy	https://clinicaltrials.gov/study/NCT04068896		ACTIVE_NOT_RECRUITING	BIOLOGICAL: NGM120\|BIOLOGICAL: NGM120\|BIOLOGICAL: NGM120\|BIOLOGICAL: NGM120\|BIOLOGICAL: NGM120\|BIOLOGICAL: NGM120\|OTHER: Placebo	NGM Biopharmaceuticals, Inc		75	INTERVENTIONAL	NGM Clinical Study Site, Tucson, Arizona, 85719, United States\|NGM Clinical Study Site, Los Angeles, California, 90048, United States\|NGM Clinical Study Site, Los Angeles, California, 90084, United States\|NGM Clinical Study Site, Sacramento, California, 98517, United States\|NGM Clinical Study Site, San Diego, California, 92123, United States\|NGM Clinical Study Site, Santa Monica, California, 90404, United States\|NGM Clinical Study Site, Aurora, Colorado, 80045, United States\|NGM Clinical Study Site, Washington, District of Columbia, 20007, United States\|NGM Clinical Study Site, Miami, Florida, 33136, United States\|NGM Clinical Study Site, Chicago, Illinois, 60611, United States\|NGM Clinical Study Site, Baltimore, Maryland, 21201, United States\|NGM Clinical Study Site, Omaha, Nebraska, 68130, United States\|NGM Clinical Study Site, Charlotte, North Carolina, 28204, United States\|NGM Clinical Study Site, Cincinnati, Ohio, 45219, United States\|NGM Clinical Study Site, Philadelphia, Pennsylvania, 19111, United States\|NGM Clinical Study Site, Charleston, South Carolina, 29425, United States\|NGM Clinical Study Site, Myrtle Beach, South Carolina, 29572, United States\|NGM Clinical Study Site, Nashville, Tennessee, 37203, United States\|NGM Clinical Study Site, Dallas, Texas, 75390, United States\|NGM Clinical Study Site, Houston, Texas, 77030, United States\|NGM Clinical Study Site, Seattle, Washington, 98101, United States\|NGM Clinical Study Site, Milwaukee, Wisconsin, 53226, United States
NCT02935478	Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation	https://clinicaltrials.gov/study/NCT02935478		SUSPENDED	DEVICE: Embospheres Microspheres	St. Louis University		8	INTERVENTIONAL	Saint Louis University, Saint Louis, Missouri, 63110, United States
NCT01047735	The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes	https://clinicaltrials.gov/study/NCT01047735	TRIABETES	ACTIVE_NOT_RECRUITING	PROCEDURE: Roux-en-Y Gastric Bypass Surgery\|PROCEDURE: Laparoscopic Adjustable Gastric Banding\|BEHAVIORAL: Lifestyle Weight Loss Intervention	University of Pittsburgh	National Institutes of Health (NIH)\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	69	INTERVENTIONAL	William F Gourash, Pittsburgh, Pennsylvania, 15213, United States
NCT05579444	Systems Biology of Gastrointestinal and Related Diseases	https://clinicaltrials.gov/study/NCT05579444		RECRUITING		Viome		100000	OBSERVATIONAL	Viome Life Sciences, Bothell, Washington, 98011, United States